| Date Filed | Type | Description |
| 01/08/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/24/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 08/23/2018 |
GN
| Biostar Pharmaceuticals Announces Receipt of Additional Delisting Determination Letter from Nasdaq |
| 07/25/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 07/06/2018 |
8-K
| Other Events |
| 07/02/2018 |
SC 13D
| Liu Waiping reports a 16.2% stake in Biostar Pharmaceuticals, Inc. |
| 05/30/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 05/16/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/23/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 04/02/2018 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/02/2018 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 02/02/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2018 |
3
| Chen Melissa Fan (Director) has filed a Form 3 on Biostar Pharmaceuticals, Inc. |
| 12/28/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/18/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/04/2017 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/20/2017 |
10-Q
| Quarterly Report for the period ended September 30, 2017 |
| 11/15/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 11/15/2017 |
10-Q
| Quarterly Report for the period ended June 30, 2017 |
| 08/28/2017 |
8-K
| Quarterly results |
| 08/15/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/12/2017 |
8-K
| Form 8-K - Current report |
| 05/19/2017 |
10-Q
| Quarterly Report for the period ended March 31, 2017 |
| 05/15/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 04/21/2017 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2017 |
10-K
| Annual Report for the period ended December 31, 2016 |
| 04/03/2017 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 02/24/2017 |
8-K
| Form 8-K - Current report |
| 02/09/2017 |
8-K
| Form 8-K - Current report |
| 01/20/2017 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 12/30/2016 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933 |
| 11/21/2016 |
10-Q
| Quarterly Report for the period ended September 30, 2016 |
| 11/15/2016 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 10/19/2016 |
SC 13G
| INTRACOASTAL CAPITAL, LLC reports a 2.1% stake in Biostar Pharmaceuticals, Inc. |
|